01 Integration of Artificial Intelligence in Cancer Biomarker Discovery The growing volume and complexity of genomic, proteomic, imaging, and clinical data is encouraging researchers to use artificial intelligence for identifying patterns linked to cancer development, diagnosis, and treatment response. This transition is making biomarker discovery more data-driven by helping researchers analyze high-dimensional datasets and identify potential molecular signatures that may be difficult to detect through conventional analysis. For example, the National Cancer Institute uses AI and machine learning to analyze genomic data for biomarker discovery, including identifying biomarkers associated with immunotherapy and detecting potential driver genes.
02 Adoption of Liquid Biopsy for Non-Invasive Cancer Detection The need for less invasive approaches to obtain cancer-related molecular information is encouraging the use of liquid biopsy based on blood-derived cell-free DNA and circulating tumor DNA. This transition is expanding biomarker testing beyond tissue samples and supports applications such as mutation detection, treatment selection, and monitoring of molecular residual disease. For example, the FDA has approved liquid biopsy tests such as FoundationOne Liquid CDx for detecting mutations in circulating cell-free DNA to help identify patients who may benefit from specific cancer treatments.
01 Early Cancer Diagnosis and Biomarker-Based Patient Stratification Drive Market The need for earlier cancer detection creates demand for biomarkers that can help identify disease-related biological changes before advanced symptoms appear. Healthcare providers use biomarker testing to support diagnosis, assess disease characteristics, and guide further clinical evaluation. For example, prostate-specific antigen (PSA) testing can help assess prostate cancer risk and determine whether additional diagnostic evaluation is needed. This clinical need supports the use of cancer biomarker tests across hospitals, diagnostic laboratories, and oncology centers.The need to match treatments with patient-specific disease characteristics creates demand for biomarkers that support patient stratification. The National Cancer Institute explains that biomarker testing can help doctors select treatments that are more likely to work for patients with specific genetic or molecular characteristics. For example, HER2 testing helps identify breast cancer patients who may be candidates for HER2-targeted therapies such as trastuzumab. This treatment-selection requirement supports the use of biomarker testing in oncology practice and clinical drug development.
01 Regulatory Requirements and Skilled Workforce Limit Market Expansion Complex regulatory requirements for cancer biomarker tests can increase the evidence, validation, and documentation needed before commercialization. FDA guidance indicates that IVD evaluations can involve analytical performance, clinical sensitivity and specificity, and clinical validity, while companion diagnostics may require additional regulatory considerations. These requirements can increase development time and costs, delay product launches, and slow the adoption of cancer biomarker technologies.Limited availability of skilled professionals in molecular diagnostics, genomics, pathology, bioinformatics, and clinical interpretation can restrict the effective use of cancer biomarker technologies. Specialized expertise is needed to perform advanced testing, interpret complex biomarker results, and integrate findings into clinical decisions. This workforce gap can reduce testing capacity and slow the growth of the cancer biomarker market.
01 Companion Diagnostics and Pharmaceutical Biomarker Partnerships Offers Growth Opportunities Diagnostic companies, oncology laboratories, and pharmaceutical firms can develop tests that identify patients eligible for specific targeted treatments. The FDA’s authorized-device list includes multiple oncology companion diagnostics, including Guardant360 CDx and FoundationOne CDx for specific cancer biomarkers, creating revenue through diagnostic kits, testing services, and drug-diagnostic partnerships.Biomarker developers, pharmaceutical companies, and diagnostic laboratories can collaborate on biomarker validation, clinical development, and patient-selection strategies. The FDA reported 12 companion-diagnostic approvals among 18 oncology IVD authorizations in 2022, highlighting the role of diagnostic–drug co-development. Such partnerships create revenue through licensing, testing services, and co-development agreements.
01 Tumor Variability and Clinical Sample Limitations Hinders Growth Genetic and molecular differences between tumors can cause the same biomarker to perform differently across patients or cancer subtypes. The National Cancer Institute notes that differences can occur both between tumors in different patients and among cancer cells within the same tumor, creating challenges for accurate diagnosis and treatment prediction. This variability can require additional validation and patient stratification, increasing development timelines and costs.Cancer biomarker development depends on well-characterized tumor tissue, blood samples, and associated clinical data from diverse patient populations. The National Cancer Institute identifies the lack of high-quality research biospecimens as a major roadblock to cancer research and notes that differences in collection, processing, storage, and associated data can affect research reproducibility. Limited access to consistent, well-annotated specimens can slow assay development and clinical validation, delaying product commercialization.
March 2026 Roche expanded its cancer diagnostics portfolio with advanced biomarker testing solutions, including next-generation sequencing and companion diagnostics technologies designed to support precision oncology and targeted cancer therapies.
January 2026 Thermo Fisher Scientific expanded its oncology diagnostics portfolio with enhanced biomarker analysis platforms, supporting genomic profiling, liquid biopsy research, and personalized cancer treatment decisions.
October 2025 Illumina expanded its oncology sequencing solutions portfolio with advanced genomic analysis technologies designed to identify cancer biomarkers and support precision medicine applications.
August 2025 Guardant Health expanded its liquid biopsy and cancer biomarker testing portfolio with improved blood-based genomic profiling solutions designed to support early cancer detection, treatment selection, and monitoring.